Signs a strategic agreement with AD Ports and unveils plans to expand into vaccines
LIFEPharma, the UAE’s only USFDA-approved pharmaceutical manufacturer and part of VPS Health, has unveiled a proposed AED 700mn advanced pharmaceutical manufacturing platform at Khalifa Economic Zones Abu Dhabi (KEZAD), following the signing of a strategic Memorandum of Understanding (MoU) with AD Ports, the parent company of KEZAD.
The signing took place on Day one of Make it in the Emirates (MIITE) 2026 in the presence of Captain Mohamed Juma Al Shamisi, Managing Director and Group CEO, AD Ports Group, and Dr. Shamsheer Vayalil, Founder and Chairman, VPS Health.
The agreement was signed byOmran Al Khoori, Director, VPS Health, and Abdullah Al Hameli, CEO, Economic Cities and Free Zones Cluster, AD Ports Group.
Significant step
The MoU marks a significant step toward establishing the proposed KEZAD manufacturing platform, with LIFEPharma leading the project’s technical, regulatory, and commercial development, and AD Ports serving as the preferred industrial platform partner in Abu Dhabi by facilitating access to land, infrastructure, utilities, and relevant government coordination.
“For families living with conditions like thalassemia or sickle cell disease, which touch so many lives in our region, this platform is about bringing the most advanced treatments closer to home and building industrial strength at the same time,” assured Dr. Vayalil.
LIFEPharma also formalized a strategic financing agreement with Ajman Bank, providing a key funding mechanism to support the project and priority development programs ahead. The KEZAD platform further strengthens the integrated healthcare and pharmaceutical capabilities being built across
